Stomach contents in tirzepatide users and fasting volunteers
Part of Digestive system clinical trials.
This study uses an ultrasound to look at the stomach contents of people who are taking tirzepatide compared to those who are not. It will help doctors understand how this medication affects stomach emptying during fasting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are currently taking tirzepatide (a medication for diabetes or weight loss).
- You have not eaten solid food for at least 8 hours and have not had any liquids with particles (like milk and juice) for at least 2 hours.
- You are not pregnant or recently gave birth.
- You do not have any condition that slows stomach emptying (like diabetes with nerve damage, scleroderma, or stomach surgery).
- You are not taking medications that speed up stomach emptying, such as bromopride, metoclopramide, or domperidone.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial examines how well tirzepatide works for weight loss in people with obesity, and how it's actually used in daily life. It may be an option if you haven't tried other obesity treatments and don't have diabetes.
This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.
This study uses an ultrasound to look at how full your stomach is after taking GLP-1 medications for diabetes or weight loss. It will help doctors understand if current fasting guidelines are safe before surgery or a colonoscopy.
This study uses ultrasound to see how quickly your stomach empties after a meal. It aims to learn more about normal stomach function in healthy adults.
This study tests a new medication called tirzepatide, given at carefully adjusted doses, to help people with obesity lose weight while reducing unwanted side effects. Tirzepatide is a newer injectable medicine that helps control appetite and blood sugar.
This trial tests if tirzepatide, a diabetes and weight loss medication, can help improve fatty liver disease in people who are overweight or have obesity. It may offer a new treatment option for managing liver health.
Hear when a new Full Stomach Status trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.